100 related articles for article (PubMed ID: 26188320)
1. Impact of implant composition of twin-screw extruded lipid implants on the release behavior.
Even MP; Bobbala S; Kooi KL; Hook S; Winter G; Engert J
Int J Pharm; 2015 Sep; 493(1-2):102-10. PubMed ID: 26188320
[TBL] [Abstract][Full Text] [Related]
2. In vivo investigation of twin-screw extruded lipid implants for vaccine delivery.
Even MP; Young K; Winter G; Hook S; Engert J
Eur J Pharm Biopharm; 2014 Jul; 87(2):338-46. PubMed ID: 24607791
[TBL] [Abstract][Full Text] [Related]
3. Twin-screw extruded lipid implants containing TRP2 peptide for tumour therapy.
Even MP; Bobbala S; Gibson B; Hook S; Winter G; Engert J
Eur J Pharm Biopharm; 2017 May; 114():79-87. PubMed ID: 28104440
[TBL] [Abstract][Full Text] [Related]
4. Immunostimulatory biodegradable implants containing the adjuvant Quil-A--Part I: Physicochemical characterisation.
Myschik J; Eberhardt F; Rades T; Hook S
J Drug Target; 2008 Apr; 16(3):213-23. PubMed ID: 18365883
[TBL] [Abstract][Full Text] [Related]
5. Immunostimulatory lipid implants containing Quil-A and DC-cholesterol.
Myschik J; McBurney WT; Rades T; Hook S
Int J Pharm; 2008 Nov; 363(1-2):91-8. PubMed ID: 18692555
[TBL] [Abstract][Full Text] [Related]
6. Immunostimulatory biodegradable implants containing the adjuvant Quil-A--Part II: In vivo evaluation.
Myschik J; McBurney WT; Hennessy T; Phipps-Green A; Rades T; Hook S
J Drug Target; 2008 Apr; 16(3):224-32. PubMed ID: 18365884
[TBL] [Abstract][Full Text] [Related]
7. New insights into process understanding of solid lipid extrusion (SLE) of extruded lipid implants for sustained protein delivery.
Vollrath M; Engert J; Winter G
Eur J Pharm Biopharm; 2018 Sep; 130():11-21. PubMed ID: 29913270
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of lipid sustained release implants containing imiquimod, alpha-galactosylceramide, or Quil-A.
Myschik J; McBurney WT; Hennessy T; Rades T; Hook S
Pharmazie; 2008 Sep; 63(9):686-92. PubMed ID: 18819523
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic studies on the release of lysozyme from twin-screw extruded lipid implants.
Sax G; Winter G
J Control Release; 2012 Oct; 163(2):187-94. PubMed ID: 22964391
[TBL] [Abstract][Full Text] [Related]
10. Long-term release and stability of pharmaceutical proteins delivered from solid lipid implants.
Vollrath M; Engert J; Winter G
Eur J Pharm Biopharm; 2017 Aug; 117():244-255. PubMed ID: 28442372
[TBL] [Abstract][Full Text] [Related]
11. Impact of change of matrix crystallinity and polymorphism on ovalbumin release from lipid-based implants.
Duque L; Körber M; Bodmeier R
Eur J Pharm Sci; 2018 May; 117():128-137. PubMed ID: 29452211
[TBL] [Abstract][Full Text] [Related]
12. Preparation and Characterization of an Oral Vaccine Formulation Using Electrosprayed Chitosan Microparticles.
Moreno JAS; Panou DA; Stephansen K; Chronakis IS; Boisen A; Mendes AC; Nielsen LH
AAPS PharmSciTech; 2018 Nov; 19(8):3770-3777. PubMed ID: 30280354
[TBL] [Abstract][Full Text] [Related]
13. Chitosan hydrogels containing liposomes and cubosomes as particulate sustained release vaccine delivery systems.
Gordon S; Young K; Wilson R; Rizwan S; Kemp R; Rades T; Hook S
J Liposome Res; 2012 Sep; 22(3):193-204. PubMed ID: 22188610
[TBL] [Abstract][Full Text] [Related]
14. Biodegradable implants for the delivery of veterinary vaccines: design, manufacture and antibody responses in sheep.
Walduck AK; Opdebeeck JP; Benson HE; Prankerd R
J Control Release; 1998 Feb; 51(2-3):269-80. PubMed ID: 9685925
[TBL] [Abstract][Full Text] [Related]
15. Preparation of lipid aspirin sustained-release pellets by solvent-free extrusion/spheronization and an investigation of their stability.
Yan X; He H; Meng J; Zhang C; Hong M; Tang X
Drug Dev Ind Pharm; 2012 Oct; 38(10):1221-9. PubMed ID: 22713120
[TBL] [Abstract][Full Text] [Related]
16. Incorporation of ovalbumin into ISCOMs and related colloidal particles prepared by the lipid film hydration method.
Demana PH; Davies NM; Berger B; Rades T
Int J Pharm; 2004 Jul; 278(2):263-74. PubMed ID: 15196631
[TBL] [Abstract][Full Text] [Related]
17. Quantitation of the immunological adjuvants, monophosphoryl lipid A and Quil A in poly (lactic-co-glycolic acid) nanoparticles using high performance liquid chromatography with evaporative light scattering detection.
Bobbala S; McDowell A; Hook S
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Jan; 975():45-51. PubMed ID: 25438242
[TBL] [Abstract][Full Text] [Related]
18. Studies on the lipase-induced degradation of lipid-based drug delivery systems. Part II - Investigations on the mechanisms leading to collapse of the lipid structure.
Schwab M; McGoverin CM; Gordon KC; Winter G; Rades T; Myschik J; Strachan CJ
Eur J Pharm Biopharm; 2013 Aug; 84(3):456-63. PubMed ID: 23385286
[TBL] [Abstract][Full Text] [Related]
19. Twin-screw extrusion of sustained-release oral dosage forms and medical implants.
Feng X; Zhang F
Drug Deliv Transl Res; 2018 Dec; 8(6):1694-1713. PubMed ID: 29235074
[TBL] [Abstract][Full Text] [Related]
20. Influence of Quil A on liposomal membranes.
Paepenmüller T; Müller-Goymann CC
Int J Pharm; 2014 Nov; 475(1-2):138-46. PubMed ID: 25107288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
